肌梭巨噬細胞MSMP氯膦酸鹽脂質(zhì)體巨噬細胞清除劑清除解決方案

荷蘭Liposoma巨噬細胞清除劑Clodronate Liposome：氯膦酸鹽脂質(zhì)體是（Liposoma，CP-005-005）是一種可以利用巨噬細胞的內(nèi)吞機制，將氯膦酸鹽帶入細胞內(nèi)，誘導巨噬細胞凋亡的試劑。它是由荷蘭阿姆斯特丹Vrije University 的Nico van Rooijen教授開發(fā)的，也叫做Clodronate Liposomes（氯膦酸二鈉脂質(zhì)體）。它是一種成熟，方便，經(jīng)濟的巨噬細胞清除方法，可以有效地清除動物體內(nèi)不同組織部位和血液中的巨噬細胞。它是研究巨噬細胞功能的重要手段。荷蘭Liposoma巨噬細胞清除劑頻繁見刊于Cell，Nature和Science。譬如剛剛2024年12月4日的一篇Narure，發(fā)現(xiàn)了巨噬細胞的全新功能，也為我們研究康復運動，肌梭巨噬細胞Muscle Spindles MacroPhages（MSMP）氯膦酸鹽脂質(zhì)體巨噬細胞清除劑清除解決方案提供了參考。

論文信息：

論文題目： Macrophages excite muscle spindles with glutamate to bolster locomotion

期刊名稱： Nature

時間期卷：Nature（2024）

在線時間：2024年12月4日

DOI：doi.org/10.1038/s41586-024-08272-5

貨號：CP-005-005

規(guī)格：5ml+5ml

品牌：Liposoma

產(chǎn)地：荷蘭

名稱：Clodronate Liposomes and Control Liposomes

注射方式：Day1一次，Day3一次

注射方式：腹腔

檢測部位：肌肉

荷蘭Liposoma巨噬細胞清除劑Clodronate Liposomes在炎性疼痛模型巨噬細胞氯膦酸鹽脂質(zhì)體清除劑解決方案清除效果圖：

荷蘭Liposoma巨噬細胞清除劑Clodronate Liposomes在炎性疼痛模型巨噬細胞氯膦酸鹽脂質(zhì)體清除劑解決方案材料和方法：

Systemic depletion of macrophages

CSF1 inhibitor, BLZ945 (4?mg per mouse per day, S7725, Selleckchem) dissolved in sterile water with 20% 2-hydroxypropyl-β-cyclodextrin (H107, Sigma) or control with 20% 2-hydroxypropyl-β-cyclodextrin were delivered to the mice for four consecutive days by oral gavage. Clodronate liposomes or control liposomes (Liposoma) were injected into mice by intraperitoneal injection (200?μl per mouse per day) on days 1 and 3. Depleted or control mice were euthanized on day 4 (4?h after the last BLZ945 gavage) or day 11. Muscles together with spinal cords and sciatic nerves were dissected and freshly processed for FACS or fixed with 4% PFA and dehydrated with 30% sucrose for cryostat sectioning followed by immunostaining. Mice without or with macrophage depletion (oral gavage of control or BLZ945 in combination with control or clodronate liposomes) were used for behavioural assessments. Mouse hindlimbs were bilaterally assessed on day 11 after depletion. Animals were randomly and equally grouped before depletion treatments (15 biological replicates for each condition). All investigators were blind to the groups and treatments.